Avacta Group Plc - On track and undervalued

Writen by Riccardo Lowi

On Track and Undervalued


  • Lead I-O program on track to reach multiple pre-clinical milestones in 2018 and to start in-human development in 2019/2020
  • Two recently announced collaborations to exploit Affimers' therapeutic potential: Affimer drug conjugates with Glythera and Affimer gene delivery with OncoSec
  • Expect further licensing deals for Affimer reagents in 2018
  • Management anticipates that financial performance for the half year to 31 January 2018 will be in line with market expectations
  • Market capitalization significantly underestimates the potential of the Affimer platform (SOTP valuation roughly 4x current market cap)


At the AGM of January 18th, Avacta reported good progress for both the Affimer therapeutic and reagents programs.

Their lead immuno-oncology development program is proceeding according to plan and multiple development milestones are expected in the course of 2018 (see next section for further details).

Besides the programs developed in-house, Avacta intends to exploit Affimers' potential through external collaborations, amongst which we count Moderna, Glythera, FIT Biotech and Phoremost.


Looking more in detail at the development of the lead Affimer therapeutic candidate, in 2018 we expect to see:
- further data from various in-vivo models on efficacy, tox and immunogenicity
- in-vitro packages on tissue distribution, T-cells activation, APC activation, PBMC
These studies shall lead to the selection of a drug candidate to enter in-human development in 2019/2020.
In the course of 2019 Avacta plans to finalize the CMC and regulatory packages, the tech transfer dossier to a CDMO and to file to an IND in 2019/2020.

On the collaboration side, Avacta made progress with several partners.

From the ongoing collaboration with FIT Biotech we expect data from a proof-of-concept study in 2Q 2018, showing how well FIT gene delivery technology works with Affimers. If positive, this can evolve into a formal drug development collaboration agreement.

The partnership with Cambridge-based drug discovery company Phoremost will trigger royalty payments to Avacta based on the revenues from products developed using Affimer technology.
Finally Avacta recently announced the positive conclusion of a pre-clinical proof-of-concept study that validates the use of Affimers in the next generation drug conjugates that Glythera is developing.

Detailed financial terms of this partnership were not disclosed, but Avacta will receive a combination of development milestone payments and royalties on Glythera's product sales.

The study showed that Affimers remain fully functional in the presence of a toxic payload, whilst offering key advantage versus full-size antibodies in terms of a shorter, simpler and cheaper development.
Besides the development and manufacturing advantages that should translate in lower manufacturing costs, Affimer drug conjugates could also be technically advantageous compared to antibody conjugates, based on better tumor penetration, a more stable link with the toxin and the ability to modulate their half-life from a few hours to a few days.
This agreement brings Affimers closer to the drug conjugate market that is expected to grow from about $1bn today to $15bn in 2030.

Finally we note that the recently established partnership with US-based OncoSec further reinforces the case for developing better alternatives to traditional antibodies.
Because of their size and biophysical properties Affimers are very good candidates for gene delivery therapies.
Avacta and OncoSec will work together to study in animal models the effect of the intra-tumor administration of Avacta's Affimer DNA - including the genome of their PD-L1 inhibitor AVA04 -, delivered via OncoSec's ImmunoPulse technology.


The first commercial deal for Affimer reagents was signed in April 2017, and represented an important milestone in the de-risking of this business line.
Based on a growing number of high profile scientific publications and ongoing paid-for evaluations, we are confident that further commercial deals will be finalized in the coming quarters.


We look at Avacta using a SOTP approach that considers separately the therapeutic programs and the reagents business.
Essentially we work out "backwards" what the implied equity value should be today, assuming Affimer products reach certain commercial levels ten years from now.

As the development of the Affimer lead oncology program proceeds through the pre-clinical development in the coming quarters, we expect the stock price to progressively rise towards our implied valuation. 
With business progressing as expected, we make no changes to our previously published SOTP table, showing an intrinsic equity value just short of £200mln or roughly 4 times current market capitalization.


We summarize below the key milestones expected in the near term



We did not make any change to our previously published financial forecasts, shown below.



Important – Please read this information: This report has been commissioned by Avacta Group PLC and prepared and issued by Capital Network for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however, we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Capital Network at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. Capital Network does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Capital Network’s solicitation to effect, or attempt to effect, any transaction in a security. This document is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Capital Network has a restrictive policy relating to personal dealing. Capital Network does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Capital Network may have a position in any or related securities mentioned in this report. Capital Network or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Capital Network within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Capital Network, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication.

Latest Research

Safety Pays

In pence-per-share terms, the NAV increased by 0.8p during the quarter. This...